Clinical Trials
2.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1693 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults
- Conditions
- Older Adults Without Any Specific Clinical ConditionSocial NetworksRSV ImmunizationVaccine Uptake
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 750
- Registration Number
- NCT07171164
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
Yoga to Improve Disparities in Cancer Survivorship
- Conditions
- SurvivorshipCancer
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT07165600
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
The Heart Health After Cardiac Treatment Study
- Conditions
- Cardiac Rehabilitation
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 100
- Registration Number
- NCT07158515
- Locations
- πΊπΈ
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
Oral vs IV Sedation for Cataract Surgery in Older Adults
- Conditions
- Cataract SurgeryPerioperative CareSedationCognition FunctionOlder Adults
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT07154147
- Locations
- πΊπΈ
UCSF Wayne and Gladys Valley Center for Vision, Mission Bay, San Francisco, California, United States
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
- Conditions
- Cutaneous MelanomaCutaneous Melanoma, Stage IIICutaneous Melanoma by AJCC V7 StageCutaneous Melanoma, Stage IV
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 300
- Registration Number
- NCT07148245
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 409
- Next
News
Achieve Life Sciences Appoints Dr. Mark Rubinstein as Interim CMO Amid Cytisinicline FDA Review
Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline.
Early Long COVID Trials of Paxlovid and Monoclonal Antibodies Show No Significant Benefits, But Research Continues
Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.
Progressive Supranuclear Palsy Market Poised for Growth as Emerging Therapies Advance Through Clinical Trials
The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.
Dispatch Bio Emerges with $216M to Develop Universal Solid Tumor Immunotherapy
Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.
Invivyd Forms SPEAR Study Group to Investigate Monoclonal Antibody Therapy for Long COVID
Invivyd has established the SPEAR Study Group with leading researchers to investigate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome, following anecdotal reports of symptom relief with PEMGARDA.
AI Tools Show Promise in Improving HER2 Breast Cancer Classification and Treatment Eligibility
A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.
Gabapentin Shows Promise in Extending Survival for Glioblastoma Patients, Mass General Brigham Study Reveals
A retrospective analysis by Mass General Brigham and UCSF researchers found that glioblastoma patients taking gabapentin lived 4-6 months longer than those who didn't receive the medication.
Trump Administration Cancels $800 Million in LGBTQ Health Research Funding
The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.
OB/GYN Workforce Shifts Following Abortion Bans: New Study Reveals Complex Migration Patterns
A new JAMA Network Open study reveals that while most OB/GYNs didn't immediately leave states with abortion bans after the 2022 Dobbs ruling, a significant decline is now occurring in the 12 most restrictive states.
Blood Test Innovations: CBC Analysis Could Revolutionize Disease Detection and Monitoring
New research shows that complete blood count (CBC) tests can identify or predict multiple diseases including heart problems, type 2 diabetes, osteoporosis, and kidney disease by analyzing individual "set points" in blood components.